Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses if there's concern over what comes when the Oncology Care Model (OCM) ends.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, discusses if there's concern over what comes when the Oncology Care Model (OCM) ends.
Transcript
Is there concern or anticipation among providers about what might come after OCM ends?
I think less concern about what might come after OCM. It’s clear that we’re going in that direction with value, and so, we have confidence that OCM will be iterated and 2.0 will be better than 1.0 was. We have a fair amount of influence on that. I’m on the [Community Oncology Alliance] board, so I have a lot of input into the COA feedback. We also use Tuple Health as our consultants; they have the ears of CMS. I actually know, personally, the soon to be named director of CMMI, who is really smart and will give us a lot of confidence in building on the successes, and I think OCM has been a success. There are some flaws like any initial system, but we have confident that 2.0 will be better than 1.0.
What are your thoughts on COA's proposed OCM 2.0? Does it address concerns that providers have with the current model?
COA’s had a lot of input and a lot of help from Tuple and Kavita Patel, MD, to help address the flaws in the current model, but also it includes some things that should probably have been in the initial model. Again, a lot of confidence with what’s coming out of COA. I just hope we can get them to implement it.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
Best of Managed Care Cast: Top 5 Episodes From the First Half of 2025
July 18th 2025These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.
Read More